Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

A New Treatment for Seborrheic Dermatitis: A Clinical Investigation

A New Treatment for Seborrheic Dermatitis: A Clinical Investigation Abstract Seborrheic dermatitis is one of those afflictions which has plagued mankind since the dawn of recorded history. As common as the common cold, it has just as stubbornly resisted any sort of treatment. During the past 100 years, few, if any new drugs have been offered which were much better than the ancient combination of sulfur and resorcinol, and other similiarly venerable but partially effective combinations. Myriads of preparations, both proprietary and nonproprietary have been offered on the market for the avowed purpose of at least giving some relief from this most distressing syndrome but with always the same result, only partial beneficial effect. Accordingly, when Kittleson* announced the discovery of a new class of organic compounds which proved to possess an unusually broad bacterial spectrum and were also exceptionally effective against a considerable number of fungi, it was thought that here was a substance which would References 1. References 1 and 2; U. S. Patent 2,553,771 (A. R. Kittleson and H. L. Yowell), May 22, 1951, assigned to Standard Oil Development Company. 2. Solution 105-6 was provided by the Pharmaceutical Division of Max Factor & Company and is being marketed under the name of "SEBB." 3. Nelson, Norton, and others: Unpublished data. 4. Kittleson, A. R.: A New Class of Organic Fungicides , Science 115:84-86, 1952.Crossref 5. Kittleson, A. R.: Preparation and Some Properties of N-Trichloromethylthiotetrahydrophthalimide. , J. Agric. & Food Chem. 1:667-679, 1953. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png A.M.A. Archives of Dermatology American Medical Association

A New Treatment for Seborrheic Dermatitis: A Clinical Investigation

A.M.A. Archives of Dermatology , Volume 71 (6) – Jun 1, 1955

Loading next page...
 
/lp/american-medical-association/a-new-treatment-for-seborrheic-dermatitis-a-clinical-investigation-b6YEwKxsMm
Publisher
American Medical Association
Copyright
Copyright © 1955 American Medical Association. All Rights Reserved.
ISSN
0096-5359
DOI
10.1001/archderm.1955.01540300018005
Publisher site
See Article on Publisher Site

Abstract

Abstract Seborrheic dermatitis is one of those afflictions which has plagued mankind since the dawn of recorded history. As common as the common cold, it has just as stubbornly resisted any sort of treatment. During the past 100 years, few, if any new drugs have been offered which were much better than the ancient combination of sulfur and resorcinol, and other similiarly venerable but partially effective combinations. Myriads of preparations, both proprietary and nonproprietary have been offered on the market for the avowed purpose of at least giving some relief from this most distressing syndrome but with always the same result, only partial beneficial effect. Accordingly, when Kittleson* announced the discovery of a new class of organic compounds which proved to possess an unusually broad bacterial spectrum and were also exceptionally effective against a considerable number of fungi, it was thought that here was a substance which would References 1. References 1 and 2; U. S. Patent 2,553,771 (A. R. Kittleson and H. L. Yowell), May 22, 1951, assigned to Standard Oil Development Company. 2. Solution 105-6 was provided by the Pharmaceutical Division of Max Factor & Company and is being marketed under the name of "SEBB." 3. Nelson, Norton, and others: Unpublished data. 4. Kittleson, A. R.: A New Class of Organic Fungicides , Science 115:84-86, 1952.Crossref 5. Kittleson, A. R.: Preparation and Some Properties of N-Trichloromethylthiotetrahydrophthalimide. , J. Agric. & Food Chem. 1:667-679, 1953.

Journal

A.M.A. Archives of DermatologyAmerican Medical Association

Published: Jun 1, 1955

References